组蛋白去乙酰化酶抑制剂靶向CD123/CD47阳性细胞并逆转急性髓系白血病化疗耐药表型
研究在白血病干细胞标志物中发现仅CD123与CD47同急性髓系白血病(AML)细胞化疗敏感性相关,化疗耐药细胞系中CD123+CD47+细胞比例显著升高。表观遗传药物尤其是组蛋白去乙酰化酶抑制剂(HDACi)可有效诱导耐药细胞凋亡,罗米地辛在移植瘤小鼠模型中优先靶向CD123+细胞并清除耐药白血病原始细胞,单用或联合阿糖胞苷可能是耐药患者的潜在治疗策略。
要点
- 在既定白血病干细胞标志物中,仅CD123与CD47同AML细胞化疗敏感性相关。
- 耐药细胞系CD123+CD47+细胞比例显著升高,但干性特征基因未见显著增加。
- 罗米地辛优先靶向CD123+细胞,阿糖胞苷主要作用于快速增殖的CD123-细胞。
核心结论
- CD123可作为AML细胞化疗耐药的生物标志物,而非干性标志物。
- HDACi尤其是罗米地辛可有效诱导化疗耐药细胞凋亡,并在移植瘤小鼠模型中靶向清除耐药白血病原始细胞。
- 罗米地辛单用或联合阿糖胞苷可能是化疗耐药患者的潜在治疗策略。
研究设计与样本
- 研究比较了多种AML细胞系及患者样本中白血病干细胞标志物与化疗敏感性的关系。
- 在化疗耐药细胞系与亲本细胞系间比较CD123+CD47+细胞比例及基因表达变化。
- 使用表观遗传药物处理耐药细胞,并在移植瘤AML小鼠模型中评估罗米地辛的靶向清除作用。
主要发现
- 在既定白血病干细胞标志物中,仅CD123和CD47与AML细胞化疗敏感性相关。
- 化疗耐药细胞系中CD123+CD47+细胞比例较亲本细胞系显著升高。
- 耐药细胞中干性特征基因未见显著增加,基因变化富集于细胞周期和细胞存活通路。
- 表观遗传药物尤其是HDACi有效诱导化疗耐药细胞凋亡。
- 罗米地辛优先靶向CD123+细胞,而阿糖胞苷主要靶向快速增殖的CD123-细胞。
临床怎么用
- 作者认为罗米地辛单用或联合阿糖胞苷可能是化疗耐药患者的潜在治疗策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chemoresistance may be due to the survival of leukemia stem cells (LSCs) that are quiescent and not responsive to chemotherapy or lie on the intrinsic or acquired resistance of the specific pool of AML cells. Here, we found, among well-established LSC markers, only CD123 and CD47 are correlated with AML cell chemosensitivities across cell lines and patient samples. Further study reveals that percentages of CD123+CD47+ cells significantly increased in chemoresistant lines compared to parental cell lines. However, stemness signature genes are not significantly increased in resistant cells. Instead, gene changes are enriched in cell cycle and cell survival pathways. This suggests CD123 may serve as a biomarker for chemoresistance, but not stemness of AML cells. We further investigated the role of epigenetic factors in regulating the survival of chemoresistant leukemia cells. Epigenetic drugs, especially histone deacetylase inhibitors (HDACis), effectively induced apoptosis of chemoresistant cells. Furthermore, HDACi Romidepsin largely reversed gene expression profile of resistant cells and efficiently targeted and removed chemoresistant leukemia blasts in xenograft AML mouse model. More interestingly, Romidepsin preferentially targets CD123+ cells, while chemotherapy drug Ara-C mainly targeted fast-growing, CD123- cells. Therefore, Romidepsin alone or in combination with Ara-C may be a potential treatment strategy for chemoresistant patients.
引用
- Yan B, Chen Q, Shimada K, et al. Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia. Leukemia. 2018. PMID: 30291336. doi:10.1038/s41375-018-0279-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。